<DOC>
	<DOCNO>NCT00407212</DOCNO>
	<brief_summary>This study investigate effect TCH346 compare placebo delay need symptomatic treatment dopaminergic agent</brief_summary>
	<brief_title>A Study Three Doses TCH346 Patients With Early Parkinson 's Disease Evaluate Safety Efficacy</brief_title>
	<detailed_description>This study investigate effect TCH346 compare placebo delay need symptomatic treatment dopaminergic agent</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Male female , age 3080 year Clinical diagnosis early stage idiopathic Parkinson 's disease Experiencing two three follow sign ; bradykinesia , rigidity , tremor Not currently take antiparkinson medication A history alcohol drug abuse past year A diagnosis psychiatric illness Patients currently take MAO inhibitor within 30 day enter study Patients hypersensitive selegiline , MAOB inhibitor , tricyclic antidepressant Additional inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>early stage idiopathic Parkinson 's disease</keyword>
</DOC>